NasdaqGS - Nasdaq Real Time Price USD

Amgen Inc. (AMGN)

269.98

+0.60

(+0.22%)

At close: 4:00 PM EDT

269.98

0.00

(0.00%)

After hours: 4:18 PM EDT

AMGEN TO SUBMIT TEPROTUMUMAB MARKETING AUTHORIZATION APPLICATION TO THE EUROPEAN MEDICINES AGENCY

Amgen (NASDAQ:AMGN) today announced the imminent submission of a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for teprotumumab, a fully human monoclonal antibody and targeted inhibitor of the insulin-like growth factor-1 receptor (IGF-1R), for the treatment of moderate to severe Thyroid Eye Disease (TED) in adults. TED is a serious, progressive, debilitating and potentially vision-threatening autoimmune disease that can cause proptosis (eye bulging), diplopia

PR Newswire 7 hours ago

AMGN
+0.22%
20 Fastest Growing Health Tech Companies in the World

In this article, we will be taking a look at the 20 fastest growing health tech companies in the world. If you do not want to learn about the trends in digital health market, head straight to the 5 Fastest Growing Health tech Companies in the World. Explosive Growth and Key Trends in the Digital […]

Insider Monkey yesterday

TDOC

SNY

GSK
Analysts Estimate Amgen (AMGN) to Report a Decline in Earnings: What to Look Out for

Amgen (AMGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks yesterday

AMGN
+0.22%
SRPT
Will Healthcare ETFs Lose Momentum as Q1 Earnings Unfold?

While the healthcare sector is expected to benefit from cutting-edge medicines, new drug approvals, technological advancements, and deal activities, it is expected to witness a modest earnings decline of 5.6% in the first quarter.

Zacks 2 days ago

PFE
+0.55%
LLY
+1.19%
AMGN
+0.22%
Why Amgen (AMGN) Outpaced the Stock Market Today

In the most recent trading session, Amgen (AMGN) closed at $271.48, indicating a +0.95% shift from the previous trading day.

Zacks 3 days ago

AMGN
+0.22%
10 Best Performing Biotech ETFs in 2024

In this article, we discuss the 10 best performing biotech ETFs in 2024. If you want to skip our detailed introduction to the biotech industry and just want to take a look at some more ETFs, go directly to the 5 Best Performing Biotech ETFs in 2024. Biotechnology is a challenging field, not ideal for […]

Insider Monkey 4 days ago

LLY
+1.19%
EXAS

NBIX
The Dividend Goldmine: 3 Shining Stocks With Growing Payouts

There is always a constant search for dependable prospects that offer stability and advancement. In the middle of this hunt, dividend stocks with growth stand out as possible bright spots that give investors a means to achieve solid returns and reliable income streams. Three exceptional businesses light up the scene in this domain with their steadfast dedication to growth and shareholder rewards. The first one, a key player in the communication services industry, demonstrates a strategic shift t

InvestorPlace 7 days ago

CMCSA

AMGN
+0.22%
Amgen (AMGN) Suffers a Larger Drop Than the General Market: Key Insights

Amgen (AMGN) concluded the recent trading session at $264.07, signifying a -0.59% move from its prior day's close.

Zacks 8 days ago

AMGN
+0.22%
Sell These 3 Blue-Chip Stocks Before the Next Earnings Stumble

When the term blue chip is thrown around, many investors hear synonyms like stability and success. Other definitions limit blue-chip stocks to the 30 companies comprising the Dow Jones Industrial Average. However, blue chip stocks should be considered as those representing long-running and well-established companies that prioritize their financial health. Moreover, these companies typically command a market capitalization numbering in the billions or even trillions of dollars. This ensures both

InvestorPlace 9 days ago

HD

AMGN
+0.22%
UNH
+0.30%
Coming FDA Approvals Could Send These 3 Drug Stocks Soaring

In the biotech and pharmaceutical world, FDA approval is the number one needle mover for drug stocks. Why? Because FDA approval for a drug or treatment can bring years or even decades of steady, high-margin revenue. This is why investors who specifically look to target drug stocks are always aware of an upcoming FDA catalyst for that company. FDA approvals are bullish whether the company is a pre-revenue startup or a global pharmaceutical giant. At the same time, FDA rejections can tank a drug s

InvestorPlace 9 days ago

AMGN
+0.22%
MRK
+0.37%
AQST
Can This High-Yield Dividend Stock Keep Beating the S&P 500?

Amgen's shares have come under pressure this year, making it a compelling bargain buy.

Motley Fool 9 days ago

AMGN
+0.22%
^GSPC
Got $5,000? Here Are 3 Undervalued Stocks to Buy and Hold Forever

Not every business in operation today is built to thrive -- or even last -- indefinitely. These are.

Motley Fool 9 days ago

DAL

AMGN
+0.22%
^GSPC
AMGEN TO PRESENT TEZSPIRE® PHASE 2A COPD DATA AT ATS 2024

Amgen (NASDAQ:AMGN) today provided an update regarding the results of the Phase 2a COURSE trial for TEZSPIRE® (tezepelumab-ekko) in chronic obstructive pulmonary disease (COPD), which were accepted for presentation in the Clinical Trials Symposium at The American Thoracic Society (ATS) 2024 International Conference on Monday, May 20, from 9:15-11:15 a.m. PDT.

PR Newswire 9 days ago

AMGN
+0.22%
The 3 Best Biotech Stocks to Buy Now: Q2 Edition

Some of the hottest opportunities can be found in biotech stocks to buy now. With innovation, mergers and acquisitions, major companies looking to replenish their pipelines ahead of patent expirations, treatments for obesity, aging baby boomers, and demand for better care are creating massive opportunities. We’re even seeing big opportunities in cancer treatments known as ADCs (antibody-drug conjugates), and in gene-editing. We can even look at the impact artificial intelligence could have on he

InvestorPlace 10 days ago

AMGN
+0.22%
AGIO

OCUL
3 Stocks to Buy Low Today With High Hopes for Tomorrow

Due to its obvious nature, one of the most commonly repeated pieces of advice regarding stock investment is to buy undervalued stocks when they trade low and sell overvalued stocks when they trade high. Achieving this outcome consistently would be ideal. However, the challenge lies not only in identifying overvalued and undervalued stocks trading at appreciated or depressed prices but also in those with promising potential.There may be several reasons why undervalued stocks do not reflect their

InvestorPlace 11 days ago

CSIQ

DSX-WS

AMGN
+0.22%
Amgen Inc. (AMGN) is Attracting Investor Attention: Here is What You Should Know

Zacks.com users have recently been watching Amgen (AMGN) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Zacks 11 days ago

AMGN
+0.22%
Amgen (AMGN) Laps the Stock Market: Here's Why

In the most recent trading session, Amgen (AMGN) closed at $270, indicating a +1.33% shift from the previous trading day.

Zacks 14 days ago

AMGN
+0.22%
Is Amgen Stock a Buy?

Amgen's stock isn't expensive, but the business does face some challenges, which could have investors thinking twice.

Motley Fool 15 days ago

AMGN
+0.22%
This weight-loss ETF has performed well in its first five months. How does it compare with cheaper alternatives?

GLP-1 medications will likely expand beyond their current uses for diabetes or weight loss, according to money managers at Tema

MarketWatch 16 days ago

NVO

VRTX
-0.06%
LLY
+1.19%
11 Best Biotech ETFs To Buy

In this article, we discuss 11 best biotech ETFs to buy. If you want to skip our discussion on the biotech industry, head over to 5 Best Biotech ETFs To Buy. The new era in biotech is defined by the convergence of biology, data, and artificial intelligence. According to The Journal of mHealth, the focus […]

Insider Monkey 17 days ago

AMGN
+0.22%
NTRA

NBIX

Performance Overview

Return	AMGN	S&P 500
YTD	-5.53%	+6.92%
1-Year	+13.96%	+25.26%
3-Year	+15.62%	+22.00%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Amgen Inc. (AMGN)

AMGEN TO SUBMIT TEPROTUMUMAB MARKETING AUTHORIZATION APPLICATION TO THE EUROPEAN MEDICINES AGENCY

20 Fastest Growing Health Tech Companies in the World

Analysts Estimate Amgen (AMGN) to Report a Decline in Earnings: What to Look Out for

Will Healthcare ETFs Lose Momentum as Q1 Earnings Unfold?

Why Amgen (AMGN) Outpaced the Stock Market Today

10 Best Performing Biotech ETFs in 2024

The Dividend Goldmine: 3 Shining Stocks With Growing Payouts

Amgen (AMGN) Suffers a Larger Drop Than the General Market: Key Insights

Sell These 3 Blue-Chip Stocks Before the Next Earnings Stumble

Coming FDA Approvals Could Send These 3 Drug Stocks Soaring

Can This High-Yield Dividend Stock Keep Beating the S&P 500?

Got $5,000? Here Are 3 Undervalued Stocks to Buy and Hold Forever

AMGEN TO PRESENT TEZSPIRE® PHASE 2A COPD DATA AT ATS 2024

The 3 Best Biotech Stocks to Buy Now: Q2 Edition

3 Stocks to Buy Low Today With High Hopes for Tomorrow

Amgen Inc. (AMGN) is Attracting Investor Attention: Here is What You Should Know

Amgen (AMGN) Laps the Stock Market: Here's Why

Is Amgen Stock a Buy?

This weight-loss ETF has performed well in its first five months. How does it compare with cheaper alternatives?

11 Best Biotech ETFs To Buy

Performance Overview